ABEONA THERAPEUTICS INC. Deferred Tax Assets, Operating Loss Carryforwards
ABEONA THERAPEUTICS INC. (ABEO) had Deferred Tax Assets, Operating Loss Carryforwards of $65.96 million as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-17
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $65.96M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $88.06M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $78.70M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $75.54M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $65.96M 10-K · filed 2026-03-17 | |
| 2024-12-31 | $88.06M 10-K · filed 2026-03-17 | |
| 2023-12-31 | $78.70M 10-K · filed 2025-03-20 | |
| 2022-12-31 | $75.54M 10-K · filed 2024-03-18 | |
| 2021-12-31 | $71.00M 10-K · filed 2023-03-29 | |
| 2020-12-31 | $61.06M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $50.80M 10-K · filed 2021-03-24 | |
| 2018-12-31 | $38.76M 10-K · filed 2020-03-16 | |
| 2017-12-31 | $50.03M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $73.86M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $68.64M 10-K · filed 2017-03-30 | |
| 2014-12-31 | $68.26M 10-K · filed 2016-03-30 | |
| 2013-12-31 | $63.09M 10-K · filed 2015-03-31 | $63.05M 10-K · filed 2014-03-26 |
| 2012-12-31 | $64.15M 10-K · filed 2014-03-26 | |
| 2011-12-31 | $63.83M 10-K · filed 2013-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |